



UNIVERSITY OF LEEDS

This is a repository copy of *Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/126458/>

Version: Supplemental Material

Article:

Sjoquist, KM, Renfro, LA, Simes, RJ et al. (31 more authors) (2017) Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. *Journal of the National Cancer Institute*, 10 (6). djx253. ISSN 0027-8874

<https://doi.org/10.1093/jnci/djx253>

© The Author 2017. Published by Oxford University Press. All rights reserved. This is a pre-copyedited, author-produced version of an article accepted for publication in *Journal of the National Cancer Institute* following peer review. The version of record Sjoquist, KM, Renfro, LA, Simes, RJ et al. (31 more authors) (2017) Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. *Journal of the National Cancer Institute*, 10 (6). djx253. ISSN 0027-8874 is available online at: <https://doi.org/10.1093/jnci/djx253>. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

APPENDIX

Using the nomogram for OS in Figure 1A, an example patient's predictions may be obtained from a single nomogram as follows. First, risk points associated with each variable are obtained via vertical translation of the patient's variable value (e.g., BRAF) to the scale labeled "Points" in the nomogram (i.e., BRAF MT status contributes approximately 29 points to risk of death). Next, the points associated with each variable value for the patient are totaled across the variables. This total is then located on the scale "Total Points" and then vertically mapped to obtain the prediction of interest (e.g., 140 Total Points maps to a 1-Year OS probability of approximately 69%). Instructions also apply to the PFS nomogram in Figure 1B.

Supplemental Table 1. ARCAD trials used for nomogram construction and validation.

Trial	Years Accrued	First Line Treatment Arms	N
03-TTD-01	2002-2004	FUOX vs. CAPOX	342
AGITG (MAX)	2005-2007	Capecitabine vs. capecitabine + bevacizumab vs. capecitabine + bevacizumab + mitomycin	471
AIO22	2002-2004	FUFOX vs. CAPOX	470
AVF2107g	2000-2002	IFL vs. IFL + bevacizumab	923
AVF2192g	2000-2002	5-FU vs. 5-FU + bevacizumab	209
BICC-C	2003-2004	mIFL +/- bevacizumab vs. FOLFIRI +/- bevacizumab vs. CapIRI	532
C97-3	1997-1999	FOLFOX6 vs. FOLFIRI	220
CAIRO	2003-2004	Capecitabine vs. CapIRI	820
CAIRO2	2005-2006	CAPOX + bevacizumab vs. CAPOX + bevacizumab + cetuximab	746
COIN	2005-2008	FOLFOX vs. FOLFOX + cetuximab vs. intermittent FOLFOX	2,418
CRYSTAL	2004-2005	FOLFIRI + cetuximab vs. FOLFIRI	1,217
FIRE II (CIOX)	2004-2006	XELOX + cetuximab vs. CapIRI + cetuximab	177
FIRE III	2007-2012	FOLFIRI + bevacizumab vs. FOLFIRI + cetuximab	592
FOCUS	2000-2003	5-FU vs. 5-FU + oxaliplatin vs. 5-FU + irinotecan	2,103
FOCUS II	2004-2006	5-FU vs. FOLFOX vs. capecitabine vs. CAPOX	397
GONO	2001-2005	FOLFOXIRI vs. FOLFIRI	244
HORG 99.30	2000-2004	FOLFOXIRI vs. FOLFIRI	283
HORIZON II	2006-2010	FOLFOX + CAPOX + cediranib vs. FOLFOX + CAPOX	1,076
HORIZON III	2006-2009	FOLFOX + cediranib vs. FOLFOX + bevacizumab	1,601
MACRO	2006-2008	XELOX + bevacizumab vs. bevacizumab	476
N016966	2004-2005	FOLFOX + CAPOX + bevacizumab vs. FOLFOX + CAPOX	2,034
N9741	1999-2001	IFL vs. FOLFOX vs. IROX	1,416
OPTIMOX 1	2000-2002	FOLFOX4 vs. FOLFOX7	621
OPTIMOX 2	2004-2006	mFOLFOX7 vs. mFOLFOX7	202
OPUS	2005-2006	FOLFOX4 vs. FOLFOX4 + cetuximab	340
PACCE (C249)	2005-2006	Chemotherapy + bevacizumab vs. Chemotherapy + bevacizumab + panitumumab	1,053
PRIME (C203)	2006-2008	FOLFOX vs. FOLFOX + panitumumab	1,183
TRIBE	2008-2011	FOLFIRI + bevacizumab vs. FOLFOXIRI + bevacizumab	508
Total ARCAD			22,674

Abbreviations: AGITG, Australasian Gastro-Intestinal Trials Group; AIO, Arbeitsgemeinschaft Internistische Onkologie; ARCAD, Aide et Recherche en Cancérologie Digestive; AVF, anastomotic-vaginal fistula; BICC, Breast Cancer in City and Country; CAIRO, Capecitabine, Irinotecan, and Oxaliplatin in Advanced Colorectal Cancer; CapIRI, capecitabine and irinotecan; CAPOX, capecitabine plus oxaliplatin; FOCUS, Fluorouracil, Oxaliplatin, and CPT11 Use and Sequencing; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; FU, fluorouracil; FUFOX, fluorouracil plus oxaliplatin; FUOX, continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin; GONO, Gruppo Oncologico Nord Ovest; HORG, Hellenic Oncology Research Group; IFL, irinotecan, leucovorin, and fluorouracil; IROX, irinotecan and oxaliplatin; m, modified; MACRO, Maintenance in Colorectal Cancer; PACCE, Panitumumab Advanced Colorectal Cancer Evaluation; XELOX, capecitabine plus oxaliplatin; 5-FU, fluorouracil and leucovorin.